e-Article
Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial.
Document Type
Article
Author
Rodríguez-Pardo, Dolors; del Toro, María Dolores; Guío-Carrión, Laura; Escudero-Sánchez, Rosa; Fernández-Sampedro, Marta; García-Viejo, Miguel Ángel; Velasco-Arribas, María; Soldevila-Boixader, Laura; Femenias, Magdalena; Iribarren, José Antonio; Pulido-Garcia, María del Carmen; Navarro, María Dolores; Lung, Mayli; Corona, Pablo S.; Almirante, Benito; Pigrau, Carles
Source
Subject
*JOINT infections
*HEMIARTHROPLASTY
*BACTERIURIA
*CLINICAL trials
*SAMPLE size (Statistics)
*
*
*
*
Language
ISSN
0934-9723
Abstract
Purpose: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Methods: Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA. Results: Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]). Conclusions: Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47 [ABSTRACT FROM AUTHOR]